Anti-PD-L1 Immunotherapy of Chronic Virus Infection Improves Virus Control without Augmenting Tissue Damage by Fibrosis
Casella, Valentina (Universitat Pompeu Fabra. Departament de Medicina i Ciències de la Vida)
Cebollada Rica, Paula (Universitat Pompeu Fabra. Departament de Medicina i Ciències de la Vida)
Argilaguet, Jordi 1977- (Unitat mixta d'investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal)
Vidal Barba, Enric (Unitat mixta d'investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal)
González-Cao, María (Hospital Quiron-Dexeus Barcelona. Instituto Oncologico Dr. Rosell)
Güerri-Fernández, Robert (Hospital del Mar)
Bocharov, Gennady (Moscow State Medical University. Institute of Computer Science and Mathematical Modeling)
Meyerhans, Andreas (Institució Catalana de Recerca i Estudis Avançats)

Date:	2024
Abstract:	Immunotherapy with checkpoint inhibitors, albeit commonly used against tumors, is still at its infancy against chronic virus infections. It relies on the reinvigoration of exhausted T lymphocytes to eliminate virus-infected cells. Since T cell exhaustion is a physiological process to reduce immunopathology, the reinvigoration of these cells might be associated with an augmentation of pathological changes. To test this possibility, we here analyzed in the model system of chronic lymphocytic choriomeningitis virus (LCMV)-infected mice whether treatment with the checkpoint inhibitor anti-PD-L1 antibody would increase CD8 T cell-dependent fibrosis. We show that pre-existing spleen fibrosis did not worsen under conditions that increase CD8 T cell functionality and reduce virus loads suggesting that the CD8 T cell functionality increase remained below its pathogenicity threshold. These promising findings should further encourage immunotherapeutic trials against chronic virus infections.
Grants:	Agencia Estatal de Investigación PID2022-141395OB-I00
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Immunotherapy ; Anti-pd-l1 ; Fibrosis ; Chronic virus infection ; LCMV
Published in:	Viruses, Vol. 16 (may 2024) , ISSN 1999-4915

DOI: 10.3390/v16050799
PMID: 38793680

9 p, 3.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Centre de Recerca en Sanitat Animal (CReSA-IRTA)
Articles > Research articles
Articles > Published articles